LA JOLLA, CA, Sept. 04, 2024 (GLOBE NEWSWIRE) — GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (NKT) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that its abstract has been accepted for a poster presentation at the 2024 European Respiratory Congress (ERS) being held September 7-11, 2024 in Vienna, Austria.
Details of the poster presentation are as follows:
Title: Type 1 Invariant Natural Killer T Cells Drive Lung Fibrosis
Presenter: Emily Calamita of Dr. Adam Byrne’s laboratory, Imperial College London
Poster Number: PA3381
Session: Novel Insights in the Pathogenesis of Pulmonary Fibrosis
Date and Time: September 9, 2024, from 12:30 – 2:00 PM CEST
For more information about the event, please visit the conference website here.
About GRI Bio, Inc.
GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio’s therapies are designed to target the activity of NKT cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type 1 invariant (iNKT) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio’s lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 NKT agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
GRI@jtcir.com
Esteemed Life Sciences Leader Joins Board to Enhance Strategic Direction During Company Expansion Ben Daverman,…
New data to be presented from Company’s lead product candidate SENTI-202 for the treatment of…
Academic research teams of selected projects participate in a translational research program that eliminates barriers…
FDA-cleared home sleep test provides an effective and simplified solution to obstructive sleep apnea testing…
$3.1 million of new orders received during the current calendar year$6.6 million customer program backlog…
ATLANTA, April 03, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a…
![](data:image/svg+xml;charset=utf-8,<svg height="32px" width="32px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="1px" width="1px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
